Search

Clinical Research

Category

San Francisco

Amneal names Allergan vet president

Amneal names Allergan vet president  Drug Store NewsFull coverage http://www.drugstorenews.com/article/amneal-names-allergan-vet-president

Advertisements

BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody …

BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody …  Markets InsiderFull coverage http://markets.businessinsider.com/news/stocks/BeiGene-Presents-Initial-Phase-1b-Data-for-BTK-Inhibitor-Zanubrutinib-BGB-3111-Combined-with-PD-1-Antibody-Tislelizumab-BGB-A317-at-the-59th-American-Society-of-Hematology-Annual-Meeting-1010950896

Pfizer breast cancer drug superior to chemotherapy in late stage study

Pfizer breast cancer drug superior to chemotherapy in late stage study  ReutersFull coverage https://www.reuters.com/article/us-pfizer-cancer/pfizer-breast-cancer-drug-superior-to-chemotherapy-in-late-stage-study-idUSKBN1E21R5

Iovance Biotherapeutics Announces Six Abstracts to be Presented at the Upcoming 2017 SITC Annual Meeting

Iovance Biotherapeutics Announces Six Abstracts to be Presented at the Upcoming 2017 SITC Annual Meeting  GuruFocus.comCalifornia State Teachers Retirement System Takes $688000 Position in Iovance Biotherapeutics Inc (NASDAQ:IOVA)  The Ledger GazetteIovance Biotherapeutics (IOVA) & Affymetrix (AFFX) Critical Review  StockNewsTimesFull coverage https://www.gurufocus.com/news/610133

Sanofi wins US approval for ‘follow-on’ Humalog insulin copy

Sanofi wins US approval for ‘follow-on’ Humalog insulin copy  BioPharma-Reporter.comSanofi Wins FDA Approval for Biosimilar of Lilly’s Humalog  NasdaqSanofi turns the tables on Lilly with biosimilar fast-acting insulin  pharmaphorumFDA approves Admelog, the first short-acting "follow-on" insulin product to treat diabetes  FDA.govFull coverage https://www.biopharma-reporter.com/Article/2017/12/13/Sanofi-wins-US-approval-for-follow-on-Humalog-insulin-copy

Gilead’s new drug keeps 56% of lymphoma trial patients alive

Gilead’s new drug keeps 56% of lymphoma trial patients alive  Pharmacy Today, American Pharmacists Association, pharmacist.comGilead Sciences’ (GILD) Kite LT Pivotal ZUMA-1 Study of Yescarta Shows 42% of Patients Remained in Response …  StreetInsider.comFull coverage http://www.pharmacist.com/article/gileads-new-drug-keeps-56-lymphoma-trial-patients-alive

Gilead commits $100 million to address HIV/AIDS epidemic in Southern US

Gilead commits $100 million to address HIV/AIDS epidemic in Southern US  HealioFull coverage https://www.healio.com/infectious-disease/hiv-aids/news/online/%7Bde3d1faf-0972-4244-bd2e-372a7ea1cc20%7D/gilead-commits-100-million-to-address-hivaids-epidemic-in-southern-us

Philly jury delivers $28M hit to J&J and Bayer over blood thinner Xarelto

Philly jury delivers $28M hit to J&J and Bayer over blood thinner Xarelto  Luxora LeaderFull coverage https://luxoraleader.com/philly-jury-delivers-28m-hit-to-jj-and-bayer-over-blood-thinner-xarelto-2/234579/

FDA Approves Lonhala Magnair to Treat COPD

FDA Approves Lonhala Magnair to Treat COPD  Pharmacy Practice NewsFull coverage http://www.pharmacypracticenews.com/FDA-Approvals/Article/12-17/FDA-Approves-Lonhala-Magnair-to-Treat-COPD/46466

Create a free website or blog at WordPress.com.

Up ↑

%d bloggers like this: